Genprex receives FDA Fast Track designation for REQORSA with Keytruda for treating NSCLC

Genprex, Inc. CEO Rodney Varner tells Proactive the FDA has granted Fast Track Designation to the company’s lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck & Co Inc (NYSE:MRK)’s Keytruda in patients with stage III or IV non-small cell lung cancer (NSCLC), where disease progressed after treatment with Keytruda.